Copyright
©The Author(s) 2018.
World J Hepatol. Sep 27, 2018; 10(9): 571-584
Published online Sep 27, 2018. doi: 10.4254/wjh.v10.i9.571
Published online Sep 27, 2018. doi: 10.4254/wjh.v10.i9.571
Table 1 Guidelines for the clinical management of hepatocellular carcinoma
Publishing year | Guidelines | Drafted by | Treatment algorithm for advanced HCC(BCLC C) | Ref. | |
Asia | 2014 | JSH-LCSGJ | Japan Society of Hepatology and Liver Cancer Study Group of Japan | HAIC (Vp1-4), Sorafenib (Vp1-3), TACE (Vp1, 2), Resection (Vp1, 2) | [6] |
2014 | KLCSG-NCC | Korean Liver Cancer Study Group and National Cancer Center | TACE, Sorafenib | [7] | |
2014 | HKLC | Hong Kong Liver Cancer | Systemic therapy, Supportive care | [8] | |
2017 | APASL | Asian-Pacific Association for the Study of the Liver | Systemic therapy (sorafenib and regorafenib), TACE for patients with no extrahepatic metastasis | [9] | |
2017 | JSH | Japan Society of Hepatology | TACE, Resection, HAIC, Molecular targeted agents | [10] | |
Europe | 2018 | EASL | European Association for the Study of the Liver | Sorafenib (sorafenib, lenvatinib, regorafenib, and cabozantinib) | [11] |
2012 | ESMO-ESDO | European Society for Medical Oncology and European Society of Digestive Oncology | Sorafenib | [12] | |
United States | 2011 | AASLD | American Association for the Study of Liver Disease | Sorafenib | [13] |
- Citation: Saeki I, Yamasaki T, Maeda M, Hisanaga T, Iwamoto T, Fujisawa K, Matsumoto T, Hidaka I, Marumoto Y, Ishikawa T, Yamamoto N, Suehiro Y, Takami T, Sakaida I. Treatment strategies for advanced hepatocellular carcinoma: Sorafenib vs hepatic arterial infusion chemotherapy. World J Hepatol 2018; 10(9): 571-584
- URL: https://www.wjgnet.com/1948-5182/full/v10/i9/571.htm
- DOI: https://dx.doi.org/10.4254/wjh.v10.i9.571